Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Sarcoma 1Genitourinary 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Stomach Neoplasms 2Lung Neoplasms 2Sarcoma 1Recurrence 1Myeloproliferative Disorders 1Multiple Myeloma 1Gastrointestinal Neoplasms 1Endometrial Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma 1Advanced Non-Small Cell Lung Cancer 1Advanced Non Small Cell Lung Cancer 1Acrocephalosyndactylia 1

Interventions

Carboplatin 24Pemetrexed 18Cisplatin 17Paclitaxel 14pembrolizumab 13Gemcitabine 8osimertinib 7durvalumab 6Docetaxel 6Nivolumab 5Erlotinib Hydrochloride 5130-nm albumin-bound paclitaxel 5capmatinib 3brigatinib 3anlotinib 3Gefitinib 3Drug Therapy 3vosaroxin 2volociximab 2sintilimab 2pralsetinib 2ensartinib 2atezolizumab 2aflibercept 2Surgical Procedures, Operative 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiation 2Oncolytic Virotherapy 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × pemigatinib × Thoracic × Clear all
NCT06551896 2024-08-13

Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Not yet recruiting
30 enrolled
BreastGastrointestinalGenitourinarySarcomaThoracic

Breast Neoplasms, Carcinoma, Carcinoma, Transitional Cell, Lung Neoplasms, Sarcoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡